Amelioration of diabetic dyslipidemia by macrocyclic binuclear oxovanadium complex on streptozotocin induced diabetic rats

Abstract

Diabetic dyslipidemia, the main causative factor for the progression of vascular complications in diabetes, is caused due to hyperglycemia and excess mobilisation of fatty acids. Recently we have reported on a novel macrocyclic binuclear oxovanadium (MBOV) complex synthesized by us with significant hypoglycemic efficacy and without any apparent toxicity on streptozotocin induced diabetic rats. In the present study, streptozotocin induced diabetic rats were treated with the vanadium complex (5 mg/kg body weight/day) for a period of 30 days and at the end of the treatment period the status of the lipid profile in the plasma, liver and kidney was evaluated. Also the fatty acid composition of liver and kidney were analysed by gas chromatography. The increased levels of lipid contents in plasma and tissues observed in diabetic rats were reverted back to near normal levels by the administration of the vanadium complex. Also the decreased levels of HDL cholesterol and increased levels of LDL cholesterol in plasma of diabetic rats were restored to near normal levels by the treatment with the vanadium complex. The altered fatty acid composition in liver and kidney were restored by the treatment. The results enhance the claim for the macrocyclic binuclear oxovanadium complex as a potent anti-diabetogenic drug.

A Non-Toxic Binuclear Vanadium(IV) Complex as Insulin Adjuvant Improves the Glycemic Control in Streptozotocin-Induced Diabetic Rats

“…Therefore, Vox2 does not affect cholesterol levels, as reported for other oxidovanadium compounds [84,85], and the period in which the experiments were conducted in this study was insufficient to detect an anti-lipemic effect. It has been reported that the metabolic effects of vanadium are dose-dependent and require more than 4 weeks for a complete response [84][85][86][87].…”

“…Nevertheless, it was reported that some compounds showing a tendency to lower diabetic hyperglycemia did not lower diabetic hyperlipidemia, and vice versa [ 63 ]. Therefore, Vox2 does not affect cholesterol levels, as reported for other oxidovanadium compounds [ 84 , 85 ], and the period in which the experiments were conducted in this study was insufficient to detect an anti-lipemic effect. It has been reported that the metabolic effects of vanadium are dose-dependent and require more than 4 weeks for a complete response [ 84 , 85 , 86 , 87 ].…”

Evaluation of Hypoglycemic Activity of Inorganic Constituents in Nelumbo nucifera Seeds on Streptozotocin-Induced Diabetes in Rats

“…Vanadium has also been shown to improve glucose homeostasis in genetically obese, hyperinsulinemic, and insulin-resistant strains of rats and mice exhibiting some of the characteristic features of type 2 diabetes [41]. Recently, we have also reported the hypoglycemic, hypolipidemic, and antioxidant properties of macrocyclic oxovanadium complexes in STZ-induced diabetic rats [42][43][44][45][46].…”